DOCSLIB.ORG

Golimumab: a New Anti-TNF Agent on the Horizon for Inflammatory Arthritis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Golimumab: a New Anti-TNF Agent on the Horizon for Inflammatory Arthritis DRUG EVALUATION Golimumab: a new anti-TNF agent on the horizon for infl ammatory arthritis Rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis are highly prevalent infl ammatory arthritides. Various conventional therapies are currently in use, and biologic therapies have also been introduced into the treatment armamentarium. Despite the remarkable effi cacy of the anti-tumor necrosis factor (TNF) agents, there still remains an unmet need for newer anti-TNF agents. A substantial number of patients do not respond to an initial anti-TNF agent, but may respond to a second one. The modes of administration of currently marketed anti-TNF agents are not particularly convenient and risk-free for all patients. An anti-TNF agent with a better safety profi le is also highly desirable. Golimumab (CNTO-148) is a high affi nity, human monoclonal antibody to TNF-α. The various ongoing trials for golimumab have shown promising results in terms of effi cacy and safety in methotrexate-naive and -resistant patients with RA, as well as in patients with RA who were previously treated with other anti-TNF agents. In addition, the effi cacy of golimumab in psoriatic arthritis and ankylosing spondylitis has also been demonstrated. KEYWORDS: golimumab, human monoclonal antibody, new anti-TNF Shweta Bhagat1, Bhaskar Dasgupta2† & Mahboob U Rahman3,4 Rheumatoid arthritis (RA), psoriatic arthritis refractory RA if one anti-TNF agent has failed, †Author for correspondence: (PsA) and ankylosing spondylitis (AS) form the while abatacept and anakinra have not been rec- 1Southend Hospital, Essex, UK majority of the infl ammatory arthritides causing ommended. Etanercept and adalimumab have 2Essex University, Westcliff e- long-term morbidity and need protracted treat- been recommended for PsA if an anti-TNF agent on-sea, Essex, SS0 0RY, UK ment. In the UK, RA affects approximately 1% is needed, and infl iximab should be used only Tel.: +44 170 248 5353 of the population [1] . There is a signifi cant differ- if there are problems with the other two anti- Fax: +44 170 248 5909 ence in prevalence estimates between northern TNF agents. NICE recommends adalimumab bhaskar.dasgupta@ European and American countries and devel- or etanercept as possible treatment for people southend.nhs.uk oping countries [2]. There is a wide variation of with severe AS who have active spinal disease 3University of Pennsylvania annual incidence of PsA (median: 6.4, range: 0.1– as assessed on two separate occasions, 12 weeks School of Medicine, PA, USA 23.1 cases per 105 inhabitants) according to a apart, and who have tried at least two NSAIDs 4Centocor R&D, Inc., PA, USA recently published systematic review of studies without success. from around the world. The prevalence esti- Etanercept is a recombinant, dimeric fusion mates vary from one case per 105 individuals in protein composed of two extracellular domains a Japanese study to 420 cases per 105 population of the human p75 TNF receptor linked to the Fc in an Italian study (median: 180) [3]. NICE esti- portion of human immunoglobulin G1 (IgG1) mated the prevalence of clinically signifi cant AS that binds to soluble and transmembrane forms of at 0.15% of the population, and an annual inci- TNF-α and lymphotoxin (TNF-β). Adalimumab dence of 6.9 per 100,000 [4]. Thus, infl ammatory is a human IgG1 monoclonal antibody (mAb) arthritides constitute a huge disease burden. directed against TNF-α that binds to soluble and Existing nonbiologic treatments have transmembrane forms of TNF-α. Infl iximab is included analgesics, corticosteroids, NSAIDs a chimeric mAb, composed of human constant and DMARDs. Biologic therapies, specifi cally regions of IgG and murine hypervariable regions. tumor necrosis factor-α (TNF-α) inhibitors, have It binds to both soluble and transmembrane been used in a wide variety of immune-mediated TNF-α. The hypervariable region segments of infl ammatory diseases and have been approved by infl iximab and adalimumab can lead to the devel- the US FDA and EMEA. Adalimumab, etaner- opment of human anti- adalimumab and anti- cept and infl iximab have been approved to treat infl iximab anti bodies, which in some patients RA, PsA and AS. Current NICE guidlines have leads to decreased effi cacy and increased chances approved the use of infl iximab, etanercept and of infusion and injection site reaction. However, adalimumab for the treatment of RA, and other the majority of patients with antibodies do not biologics like rituximab have been approved for have any clinical consequences [5,6]. 10.2217/17584272.4.1.15 © 2009 Future Medicine Ltd Int. J. Clin. Rheumatol. (2009) 4(1), 15–23 ISSN 1758-4272 15 DREVIEWRUG EVALUATIONAuthors Bhagat, Dasgupta & Rahman Despite their effi cacy in randomized clinical Pharmacokinetics & metabolism trials, there are some limiting factors of indi- The fi rst in-human Phase I study published in vidual agents contributing to both restriction 2007 was a randomized, double-blind, placebo- in therapeutic effi cacy and treatment-limiting controlled, parallel-group, dose-escalating study adverse effects. Even in diseases where anti-TNF conducted at two sites in the USA. Six groups of treatments have been proven to be successful, adult subjects with RA were randomly assigned to more than a third of patients do not respond receive a single intravenous infusion dose of goli- adequately to treatment [7]. This may be due to mumab of 0.1, 0.3, 1, 3, 6 or 10 mg/kg. Following differing mechanisms of disease, different bind- intravenous administration, serum concentrations ing properties of each of the antagonists to TNF of golimumab declined biexponentially, with a molecules and different dissociation rates [8,9]. median t½ of 19.3 days for the 10 mg/kg group. The binding to soluble and transmembrane The median half-life appeared to increase with an TNF receptors may also activate several dif- increase in dose [11] . No dose adjustment accord- ferent cascades. Finally, the genetic makeup of ing to body weight appeared to be necessary individuals may dictate response to biological based on the fi ndings of this study. Detectable treatments. When an individual fails to respond concentrations of golimumab were observed in to one biologic treatment, a switch to another the majority of subjects through week 4, even biologic is often successful [10] . those in the lower dose groups. Estimates based Despite being highly effective and generally on a population pharmacokinetics model also well-tolerated, anti-TNF agents can lead to seri- suggest that the t½ of golimumab ranges from ous adverse reactions (serious infections including 2 to 3 weeks. sepsis), TB immunogenic reactions (lupus-like Another multicenter, randomized, double- syndromes) and hypersensitivity-type reactions blind, placebo-controlled, dose-ranging study (including infusion and injection-site reactions). reported similar results. Median trough con- The current modes of delivery of these biologic centrations increased as the dose increased, and anti-TNF agents remain extremely inconvenient attained steady state by week 12 for all goli- for patients. While oral administration of such mumab dosage groups (50 mg every 4 weeks, large protein molecules (approximately 150 kD) 50 mg every 2 weeks, 100 mg every 4 weeks does not seem to be feasible in the near future, and 100 mg every 2 weeks) [12] . However, there other modes of administration, including less was much variability between patients. A study frequent subcutaneous injections, could provide of golimumab in PsA patients identifi ed several substantial relief for patients. co-variates that affected the apparent clearance Clearly, there is a need for future research of golimumab. Of these, weight, antibody to aimed at innovations to improve and extend golimumab status, baseline C-reactive protein the therapeutic use and safety of biological (CRP) and smoking status were identifi ed as agents. Golimumab, with monthly subcutane- signifi cant co-variates [13] . ous administration, is one such newer anti-TNF agent developed for use in the infl ammatory Clinical effi cacy of golimumab in trials arthritides. Phase II trial in RA This was the fi rst study reporting the effi cacy Introduction to the compound: of golimumab in humans. This study enrolled chemistry & formulation patients with active RA despite treatment with Golimumab (CNTO-148) is a high affi nity, MTX [12] . This was a dose-fi nding study that human mAb to TNF-α. The constant regions evaluated four dosing regimens of golimumab of the heavy and light chains of golimumab are in combination with MTX, compared with identical in amino acid sequence to the corre- MTX alone. A total of 172 adult patients with sponding human constant regions of infl ixi- RA that had been active for at least 3 months mab. The antibody neutralizes both soluble and while on MTX, and were on a stable dose of membrane-bound forms of TNF-α. MTX during the 4 weeks prior to study entry, Golimumab is the fi rst anti-TNF agent with were randomly assigned to one of fi ve treatment both subcutaneous and intravenous formulations, groups: placebo plus MTX, 50 mg golimumab requiring less frequent administration compared every 4 weeks plus MTX, 50 mg every 2 weeks with current anti-TNF products. Golimumab plus MTX, 100 mg every 4 weeks plus MTX and is intended to be used as monotherapy or in 100 mg every 2 weeks plus MTX. The primary combination with metho trexate (MTX). end point of a greater proportion of patients in 16 Int. J. Clin. Rheumatol. (2009) 4(1) future science group Golimumab: a new anti-TNF agent on the horizon for infl ammatory arthritis DRUG EVALUATION the combined golimumab plus MTX groups, serum CRP concentration compared with the and at least one of the individual golimumab other three dose groups. Both the 50 and 100 mg plus MTX groups achieving ACR20 at week 16 every 4 weeks dosing demonstrated adequate compared with the placebo plus MTX group effi cacy.
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Clinical Policy: Baricitinib (Olumiant) Reference Number: ERX.SPA.291 Effective Date: 07.24.18 Last Review Date: 11.18 Revision Log
    Clinical Policy: Baricitinib (Olumiant) Reference Number: ERX.SPA.291 Effective Date: 07.24.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Baricitinib (Olumiant®) is Janus kinase (JAK) inhibitor. FDA Approved Indication(s) Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation(s) of use: Use of Olumiant in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Olumiant is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Rheumatoid Arthritis (must meet all): 1. Diagnosis of RA; 2. Prescribed by or in consultation with a rheumatologist; 3. Age ≥ 18 years; 4. Member meets one of the following (a or b): a. Failure of a ≥ 3 consecutive month trial of methotrexate (MTX) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; b. If intolerance or contraindication to MTX (see Appendix D), failure of a ≥ 3 consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 5.
    [Show full text]
  • Immunosuppressant Drugs Therapy with COVID-19
    Immunosuppressant Drugs Therapy with COVID-19: Associated Risks, Drug-Drug Interactions & Contraindications Debjyoti Talukdar1, Diane Ignacio2, and Madan Mohan Gupta2 1Teerthanker Mahaveer University 2The University of the West Indies at St Augustine September 24, 2020 Abstract Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase the mortality and morbidity, as a weakened immune system can lead to longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and its associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organisation), U.S FDA (Food and Drug Administration) and other accredited global health organisa- tions. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications and drug-drug interactions. Our study will help government partners and international health organisations to better understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised and organ transplant patients will help lower the mortality and morbidity associated with the disease amid COVID-19 pandemic. 1. INTRODUCTION As per the U.S Department of Health and Human Services and U.S FDA, immunosuppressant drugs can cause susceptibility to viruses leading to infection with increase in morbidity of the disease. It can cause severe risk of illness from COVID-19 due to a weakened immune system.
    [Show full text]
  • Infliximab, Adalimumab and Golimumab for Treating Moderately
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 39 MAY 2016 ISSN 1366-5278 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey, Hasan Basarir, John Stevens, Christopher Carroll, Anna Cantrell, Alan Lobo and Sami Hoque DOI 10.3310/hta20390 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Rachel Archer,1* Paul Tappenden,1 Shijie Ren,1 Marrissa Martyn-St James,1 Rebecca Harvey,1 Hasan Basarir,1 John Stevens,1 Christopher Carroll,1 Anna Cantrell,1 Alan Lobo2 and Sami Hoque3 1Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK 3Barts Health NHS Trust, London, UK *Corresponding author Declared competing interests of authors: none Published May 2016 DOI: 10.3310/hta20390 This report should be referenced as follows: Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20(39). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • Benlysta® (Belimumab)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1227-6 Program Prior Authorization/Notification Medication Benlysta® (belimumab)* *This program applies to the subcutaneous formulation of belimumab P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021 Effective Date 10/1/2021; Oxford only: 10/1/2021 1. Background: Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 2. Coverage Criteria: A. Systemic Lupus Erythematosus 1. Initial Authorization a. Benlysta will be approved based on all of the following criteria: (1) Diagnosis of systemic lupus erythematosus -AND- (2) Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB] -AND- (3) Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate] -AND- (4) Patient does not have severe active central nervous system lupus -AND- (5) Patient is not receiving Benlysta in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)] © 2021 UnitedHealthcare Services, Inc. 1 (b) Lupkynis (voclosporin) Authorization will be issued for 12 months.
    [Show full text]
  • Attachment: Extract from Clinical Evaluation: Etanercept
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for etanercept Proprietary Product Name: Erelzi Sponsor: Novartis Pharmaceuticals Australia Pty Ltd First round report: June 2017 Second round report: August 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. · An AusPAR is a static document; it provides information that relates to a submission at a particular point in time.
    [Show full text]
  • Heart Failure and Drug-Induced Lupus
    Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush John J. Cush, MD, Chief, Rheumatology ABSTRACT demyelinating disease, cytopenias, auto- and Clinical Immunology, Presbyterian Serious and unexpected adverse events, immune disorders, and heart failure. Hospital of Dallas, Clinical Professor of such as heart failure and drug-induced Other essays in this volume address the Internal Medicine, The University of Texas lupus, have been reported in patients subject of infection (10), demyelination Southwestern Medical School, Dallas, Texas, USA. receiving TNF inhibitor therapy. These (11), and lymphoma (12). This review events generally are easily recogniz- will focus on heart failure and lupus- Please address correspondence to: John J. Cush, MD, Presbyterian Hospital able, although they cannot be predicted like disease, which are rarely seen in of Dallas, 8200 Walnut Hill Lane, Dallas, nor avoided, other than by drug avoid- association with TNF inhibitor therapy Texax 75231-4496, USA. ance altogether. Many patients have and are currently without explanation. Clin Exp Rheumatol 2004; 22 (Suppl. 35): great benefit from anti-TNF therapies. S141-S147. Their intelligent use requires a firm Sources of data © Copyright CLINICAL AND EXPERIMENTAL understanding of these rare toxicities, As a consequence of drug approval, RHEUMATOLOGY 2004. so as to minimize the morbidity associ- manufacturers have a responsibility to ated with their uncommon occurrence. collect safety data actively and report Key words: TNF inhibitors, conges- these data to the appropriate agencies. tive heart failure, drug-induced lupus, Introduction For example, in the USA a manufactur- rheumatoid arthritis. The introduction of biologic agents to er must submit periodic safety reports specifically inhibit the pro-inflammato- to the FDA twice yearly (March and ry cytokine, tumor necrosis factor (TNF), September).
    [Show full text]
  • A New Venue of TNF Targeting
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 April 2018 doi:10.20944/preprints201804.0015.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2018, 19, 1442; doi:10.3390/ijms19051442 1 Review 2 A new venue of TNF targeting 3 Sophie Steeland1, Claude Libert2 and Roosmarijn E. Vandenbroucke3,* 4 1 Barriers in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical Molecular 5 Science, Ghent University, Ghent Belgium; [email protected] 6 2 Mouse Genetics in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical 7 Molecular Science, Ghent University, Ghent Belgium; [email protected] 8 3 Barriers in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical Molecular 9 Science, Ghent University, Ghent Belgium; [email protected] 10 * Correspondence: [email protected]; Tel.: +32 9 331 35 87 11 Received: date; Accepted: date; Published: date 12 13 Abstract: The first FDA-approved drugs were small, chemically-manufactured and highly active 14 molecules with possible off-target effects. After this first successful wave of small drugs, biotechnology 15 allowed the development of protein-based medicines such as antibodies. Conventional antibodies bind 16 a specific protein and are becoming increasingly important in the therapeutic landscape. A very 17 prominent class of biologicals are the anti-TNF drugs that are applied in several inflammatory diseases 18 that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the 19 treatment of diseases such as Crohn’s disease. However, these inhibitors also have undesired effects, 20 some of them directly associated with the inherent nature of this drug class such as immunogenicity, 21 whereas others are linked with their mechanism of action.
    [Show full text]
  • Diabetes Reduces Mesenchymal Stem Cells in Fracture Healing Through a Tnfα-Mediated Mechanism
    Diabetologia DOI 10.1007/s00125-014-3470-y ARTICLE Diabetes reduces mesenchymal stem cells in fracture healing through a TNFα-mediated mechanism Kang I. Ko & Leila S. Coimbra & Chen Tian & Jazia Alblowi & Rayyan A. Kayal & Thomas A. Einhorn & LouisC.Gerstenfeld& Robert J. Pignolo & Dana T. Graves Received: 31 July 2014 /Accepted: 19 November 2014 # Springer-Verlag Berlin Heidelberg 2014 Abstract (Sca-1) antibodies in areas of new endochondral bone forma- Aims/hypothesis Diabetes interferes with bone formation and tion in the calluses. MSC apoptosis was measured by TUNEL impairs fracture healing, an important complication in humans assay and proliferation was measured by Ki67 antibody. In and animal models. The aim of this study was to examine the vitro apoptosis and proliferation were examined in C3H10T1/ impact of diabetes on mesenchymal stem cells (MSCs) during 2 and human-bone-marrow-derived MSCs following transfec- fracture repair. tion with FOXO1 small interfering (si)RNA. Methods Fracture of the long bones was induced in a Results Diabetes significantly increased TNFα levels and streptozotocin-induced type 1 diabetic mouse model with or reduced MSC numbers in new bone area. MSC numbers were without insulin or a specific TNFα inhibitor, pegsunercept. restored to normal levels with insulin or pegsunercept treat- MSCs were detected with cluster designation-271 (also ment. Inhibition of TNFα significantly reduced MSC loss by known as p75 neurotrophin receptor) or stem cell antigen-1 increasing MSC proliferation and decreasing MSC apoptosis in diabetic animals, but had no effect on MSCs in normoglycaemic animals. In vitro experiments established Kang I. Ko and Leila S.
    [Show full text]
  • (Human) ELISA Kit Rev 07/18 (Catalog # E 4398 - 100, 100 Assays, Store at 4°C) I
    FOR RESEARCH USE ONLY! TM BioSim anti-Ipilimumab (Yervoy®) (Human) ELISA Kit rev 07/18 (Catalog # E4398-100, 100 assays, Store at 4°C) I. Introduction: Ipilimumab (Yervoy®) is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyteassociated antigen 4), a molecule on T- cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Ipilimumab ELISA kit is designed to detect antibody against Ipilimumab with high specificity and sensitivity in biological matrices. II. Application: This ELISA kit is used for in vitro qualitative determination of antibody against Ipilimumab in serum and plasma Cross Reactivity: Ipilimumab (Yervoy®) infusion camouflages/masks the presence of antibody to Ipilimumab (ATP) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATP. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Ipilimumab. III. Sample Type: Human serum and plasma IV. Kit Contents: Components E4398-100 Part No. Micro ELISA Plate 1 plate E4398-100-1 Positive Control 0.25 ml E4398-100-2 Negative Control 0.5 ml E4398-100-3 Assay Buffer 12 ml E4398-100-4 Peroxidase Conjugate 12 ml E4398-100-5 TMB substrate (Avoid light) 12 ml E4398-100-6 Stop Solution 12 ml E4398-100-7 Wash buffer (20X) 50 ml E4398-100-8 Plate sealers 2 E4398-100-9 V.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]